Increased interleukin-1β converting enzyme expression and activity in Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 6, 1999, Pages 582-587

  Zhu, S G ^a   Sheng, J G ^b   Jones, R A ^d   Brewer, M M ^b   Zhou, X Q ^b   Mrak, R E ^c   Griffin, W Sue T ^b,e  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer disease; ICE; Interleukin 1; Interleukin 1 converting enzyme; TUNEL

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BRAIN; CASE CONTROL STUDY; DNA DAMAGE; GENETICS; METABOLISM; NICK END LABELING; WESTERN BLOTTING;

ALZHEIMER DISEASE; BLOTTING, WESTERN; BRAIN; CASE-CONTROL STUDIES; CASPASE 1; DNA DAMAGE; FEMALE; HUMANS; IN SITU NICK-END LABELING; MALE; RNA, MESSENGER;

EID: 0032588231     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199906000-00002     Document Type: Article

References (37)

1. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13
2. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993;75:641-52
3. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/ CED-3 protease nomenclature. Cell 1996;87:171
4. Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85:817-27
5. Griffin WST, Stanley LC, Ling C et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989;86:7611-15
6. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease. J Neuropath Exp Neurol 1995;54:276-81
7. Sheng JG, Mrak RE, Griffin WST. Microglial interleukin-1α expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1995;21: 290-301
8. Mackenzie IR, Hao C, Munoz DG. Role of microglia in senile plaque formation. Neurobiol Aging 1995;16:797-804
9. Sheng JG, Mrak RE, Griffin WST. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer's disease. J Neuropathol Exp Neurol 1998;57:714-17
10. + astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 1997;56:285-90
11. Sheng JG, Mrak RE, Griffin WST. Progressive neuronal DNA damage associated with neurofibrillary tangle formation in Alzheimer's disease. J Neuropathol Exp Neurol 1998;57:323-28
12. Desjardins P, Ledoux S. Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex. Neurosci Lett 1998;244: 69-72
13. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-86
14. Li Y, Wang J, Sheng JG, Liu L, et al. S100β increases levels of β amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998;71:1421-28
15. Kaushal GP, Ueda N, Shah SV. Role of caspases (ICE/CED 3 proteases) in DNA damage and cell death in response to a mitochondrial inhibitor, antimycin A. Kidney Intl 1997;52:438-45
16. Black RA, Kronheim SR, Cantrell M, et al. Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J Biol Chem 1988;263:9437-42
17. Kostura MJ, Tocci MJ, Limjuco G, et al. Identification of a monocyte specific pre-interleukin 1β convertase activity. Proc Natl Acad Sci USA, 1989;86:5227-31
18. Sleath PR, Hendrickson RC, Kronheim SR, March CJ, Black RA. Substrate specificity of the protease that processes human interleukin-1β. J Biol Chem 1990;265:14526-28
19. Miller DK, Ayala JM, Egger LA, et al. Purification and characterization of active human interleukin-1β-converting enzyme from THP.1 monocytic cells. J Biol Chem 1993;268:18062-69
20. Keane RW, Srinivasan A, Foster LM, et al. Activation of CPP32 during apoptosis of neurons and astrocytes. Cell 1997;48:168-80
21. Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 1990;11:169-73
22. Ju JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for DNA fragmentation in neurons in the AD brain. NeuroReport 1994;5:2529-33
23. Johnson EM. Possible role of neuronal apoptosis in Alzheimer's disease. Neurobiol Aging 1994;15(Suppl 2):S187-S189
24. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuro-Report 1994;5:2529-33
25. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Molec Neurobiol 1995;10: 19-45
26. Lassmann H, Bancher C, Breitschopf H et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 1995;89:35-41
27. Smale G, Nichols NY, Brady DR, Finch CE, Horton WE. Evidence for apoptotic cells death in Alzheimer's disease. Exp Neurol 1995; 133:225-30
28. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996;16:1710-19
29. Troncoso JC, Sukhov RR, Kawas CH, Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: Correlations with senile plaques and disease progression. J Neuropath Exp Neurol 1996;55:1134-43
30. Stadelmann C, Brück W, Bancher C, Jellinger K, Lassmann H. Alzheimer's disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 1998;57:456-64
31. Petito CK, Roberts B. Effect of postmortem interval on in situ end-labelling of DNA oligonucleosomes. J Neuropathol Exp Neurol 1995;54:761-65
32. Brenneman DE, Page SW, Schultzberg M, et al. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms. J Pharmacol Exp Ther 1992;266:1029-35
33. Griffin WST, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: The potential role of a "cytokine cycle" in disease progression. Brain Pathol 1998;8:65-72
34. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988;8:2485-90
35. Griffin WST, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW. Microglial interleukin-1α expression in human head injury: Correlations with neuronal and neuritic β-amyloid precursor protein expression. Neurosci Lett 1994;176:133-36
36. Griffin WST, Sheng JG, McKenzie JE, et al. Life-long overexpression of S100β in Down's syndrome: Implications for Alzheimer pathogenesis. Neurobiol Aging 1998;19:401-5
37. Thornberry NA. Interleukin-1β converting enzyme. Meth Enzymol 1994;344:615-30